About RenovoRx
RenovoRx (NASDAQ:RNXT) is a biopharmaceutical company focused on developing innovative treatments for cancer, particularly pancreatic and bile duct cancer. The firm is committed to advancing its flagship product, RenovoGem, a therapy that combines chemotherapy with RenovoRx's patented intra-arterial delivery system. This unique approach aims to maximize the efficacy of cancer treatment by delivering drugs directly to the tumor site, thus reducing systemic side effects and improving patient outcomes. Among its projects, RenovoRx is involved in several clinical studies designed to test the safety and effectiveness of its treatments in patients. The company's primary goals include pushing the boundaries of cancer treatment to provide more effective solutions, obtaining regulatory approval for its products, and ultimately improving the quality of life for patients battling these challenging diseases.
Snapshot
Operations
Produtos e/ou serviços de RenovoRx
- RenovoGem, a proprietary therapy combining chemotherapy with RenovoRx's Trans-Arterial Micro-Perfusion for targeted pancreatic and bile duct cancer treatment.
- Trans-Arterial Micro-Perfusion (TAMP) technology, designed to deliver chemotherapy directly to tumors, increasing effectiveness and reducing systemic exposure.
- RenovoCath, a dual-balloon catheter that enables precise, localized delivery of therapies to solid tumors via TAMP.
- Pipeline development focusing on extending TAMP technology applications beyond pancreatic and bile duct cancers to treat other solid tumors.
- Research collaborations aimed at advancing the understanding and efficacy of targeted drug delivery to solid tumors through TAMP.
- Patient support services providing assistance with treatment access, educational resources, and support for those undergoing therapy with their technologies.
equipe executiva do RenovoRx
- Dr. Ramtin Agah M.D.Founder, Chairman of Board & Chief Medical Officer
- Mr. Shaun R. BagaiCEO, Secretary & Director
- Ms. Leesa GentryChief Clinical Officer
- Mr. Robert StrasserVice President of Operations and R&D
- Mr. Ronald B. Kocak CPA, CGMAVP, Controller & Principal Accounting Officer
- Mr. Ryan WittSenior VP and Head of Corporate Strategy & Partnerships